COM:UNITYBIOTECHNOLOGY
Unity Biotechnology
- Stock
Last Close
1.17
21/11 21:00
Market Cap
24.34M
Beta: -
Volume Today
51.60K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|
average inventory | |||||||||
average payables | 1.67M - | 3.61M 116.19% | 5.02M 38.85% | 3.87M 22.82% | 2.27M 41.33% | 1.89M 16.91% | 1.58M 16.03% | ||
average receivables | 691K - | 691K 0% | |||||||
book value per share | -120.84 - | 264.28 318.71% | 56.84 78.49% | 27.67 51.32% | 16.29 41.11% | 10.67 34.50% | 7.04 34.03% | 0.00 99.97% | |
capex per share | -6.53 - | -4.91 24.73% | -0.45 90.90% | -0.36 18.69% | -0.13 65.07% | -0.03 72.49% | -0.01 71.06% | ||
capex to depreciation | -14.67 - | -1.30 91.17% | -0.58 55.24% | -0.60 2.72% | -0.19 68.55% | -0.07 63.85% | -0.04 34.96% | ||
capex to operating cash flow | 0.14 - | 0.04 67.82% | 0.02 49.30% | 0.02 1.90% | 0.01 62.34% | 0.00 47.52% | 0.00 56.53% | ||
capex to revenue | -1.22 - | -0.04 - | -0.41 897.97% | ||||||
cash per share | 259.75 - | 251.68 3.11% | 60.54 75.95% | 29.22 51.73% | 19.21 34.27% | 15.78 17.85% | 9.98 36.73% | 0.00 99.97% | |
days of inventory on hand | |||||||||
days payables outstanding | |||||||||
days sales outstanding | 365 - | ||||||||
debt to assets | 0.41 - | 0.41 1.78% | 0.38 7.88% | 0.36 5.91% | |||||
debt to equity | 0.77 - | 0.87 12.97% | 0.71 18.15% | 0.83 17.00% | |||||
dividend yield | 0.13 - | 0.00 99.94% | |||||||
earnings yield | -0.53 - | -0.78 46.88% | -0.17 78.70% | -0.24 43.23% | -0.34 44.80% | -0.74 113.75% | -2.22 201.29% | -0.00 99.94% | |
enterprise value | -32.05M - | 49.93M 255.78% | 444.39M 789.97% | 277.06M 37.65% | 307.70M 11.06% | 100.14M 67.45% | 60.64M 39.45% | 28.52B 46,928.95% | |
enterprise value over ebitda | 3.44 - | -1.13 132.75% | -6.31 460.22% | -3.00 52.49% | -3.42 14.02% | -1.74 49.13% | -1.08 38.18% | -638.43 59,249.74% | |
ev to operating cash flow | 1.95 - | -1.30 166.60% | -7.85 502.89% | -3.83 51.25% | -3.93 2.68% | -2.22 43.42% | -1.19 46.53% | ||
ev to sales | 36.13 - | 20.93 - | 256.94 1,127.41% | ||||||
free cash flow per share | -54.23 - | -116.51 114.82% | -20.48 82.42% | -16.96 17.15% | -15.53 8.47% | -8.11 47.78% | -5.38 33.59% | ||
free cash flow yield | -0.33 - | -0.70 114.82% | -0.13 82.00% | -0.24 86.84% | -0.30 25.94% | -0.56 87.41% | -1.97 253.88% | ||
graham net net | -142.26 - | 222.16 256.17% | 53.22 76.04% | 22.23 58.23% | 4.77 78.54% | 4.11 13.86% | 3.93 4.40% | 0.00 99.99% | |
graham number | 490.40 - | 878.93 79.23% | 185.91 78.85% | 103.37 44.40% | 81.37 21.28% | 50.82 37.54% | 31.04 38.92% | 0.01 99.97% | |
income quality | 0.54 - | 0.86 59.26% | 0.74 13.72% | 0.88 18.91% | 0.83 5.28% | 0.74 11.10% | 0.85 14.75% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -23.99 - | -72.70 - | -17.84 75.47% | -16.18 9.28% | 18.22 212.58% | ||||
interest debt per share | 1.17 - | 12.74 - | 9.81 23.01% | 5.36 45.31% | 0.00 99.97% | ||||
inventory turnover | |||||||||
invested capital | 0.77 - | 0.87 12.97% | 0.71 18.15% | 0.83 17.00% | |||||
market cap | 57.23M - | 57.23M 0% | 459.67M 703.17% | 314.53M 31.57% | 266.53M 15.26% | 81.49M 69.43% | 26.01M 68.08% | 28.51B 109,503.63% | |
net current asset value | -44.77M - | 77.70M 273.53% | 152.28M 95.99% | 98.97M 35.01% | 27.43M 72.29% | 25.36M 7.53% | 39.03M 53.91% | 9.31M 76.14% | |
net debt to ebitda | 9.59 - | 0.16 98.28% | 0.22 31.75% | 0.41 86.95% | -0.46 212.79% | -0.32 29.18% | -0.61 89.49% | -0.08 86.38% | |
net income per share | -88.45 - | -129.91 46.88% | -27.02 79.20% | -17.16 36.49% | -18.06 5.23% | -10.76 40.44% | -6.08 43.46% | -0.00 99.96% | |
operating cash flow per share | -47.71 - | -111.59 133.92% | -20.03 82.05% | -16.60 17.12% | -15.40 7.23% | -8.07 47.58% | -5.37 33.42% | ||
payables turnover | |||||||||
receivables turnover | 1 - | ||||||||
research and ddevelopement to revenue | 27.04 - | 8.03 - | 156.18 1,846.12% | ||||||
return on tangible assets | -0.31 - | -0.44 39.14% | -0.42 3.77% | -0.50 17.55% | -0.59 18.70% | -0.48 18.08% | -0.46 3.54% | -0.61 30.66% | |
revenue per share | 4.02 - | 0.86 - | 0.02 97.10% | ||||||
roe | 0.73 - | -0.49 167.16% | -0.48 3.28% | -0.62 30.47% | -1.11 78.70% | -1.01 9.07% | -0.86 14.29% | -1.40 62.48% | |
roic | 0.63 - | -0.49 178.28% | -0.51 4.93% | -0.68 31.56% | -0.51 24.86% | -0.40 21.98% | -0.39 0.96% | -0.59 50.62% | |
sales general and administrative to revenue | 6.96 - | 4.82 - | 88.77 1,741.87% | ||||||
shareholders equity per share | -120.84 - | 264.28 318.71% | 56.84 78.49% | 27.67 51.32% | 16.29 41.11% | 10.67 34.50% | 7.04 34.03% | 0.00 99.97% | |
stock based compensation to revenue | 2.20 - | 2.41 - | 39.74 1,545.66% | ||||||
tangible asset value | -41.54M - | 90.84M 318.71% | 160.69M 76.89% | 120.71M 24.88% | 82.88M 31.34% | 59.57M 28.13% | 66.85M 12.22% | 28.40M 57.52% | |
tangible book value per share | -120.84 - | 264.28 318.71% | 56.84 78.49% | 27.67 51.32% | 16.29 41.11% | 10.67 34.50% | 7.04 34.03% | 0.00 99.97% | |
working capital | 89.72M - | 80.98M 9.74% | 156.38M 93.11% | 112.27M 28.21% | 86.40M 23.04% | 73.89M 14.49% | 76.92M 4.10% | 38.77M 49.60% |
All numbers in (except ratios and percentages)